Iatia's cash flow prompts ASX query
05 August, 2003 by Melissa TrudingerMicroscopy company Iatia has received a 'please explain' from the Australian Stock Exchange after its fourth quarter results showed the company had a net negative operating cash flow for the quarter of AUD$671,000 and $296,000 cash remaining.
CSIRO adds commerce to board
04 August, 2003 by Jeremy TorrCSIRO has beefed up its board with two new non-executive members, one of whom -- Brian Keane -- is a former CEO of insurance giant AAMI. The other is Prof Alan Robson, vice-chancellor elect of the University of Western Australia.
NSW research review team named
01 August, 2003 by Jeremy TorrThe NSW government has named a team responsible for reviewing the state's overall medical and health research program.
Sydney Uni first in Aust to license GTG patents
29 July, 2003 by Melissa TrudingerThe University of Sydney has become the first research institution in Australia to be granted a non-exclusive research licence by Genetic Technologies (GTG) to use its controversial non-coding DNA patents.
Private-public R&D interaction 'hit and miss': report
29 July, 2003 by Jeremy TorrIf Australia is to keep up with the rest of the world, it will have to make more of its public research institutes. According to a report jointly compiled by Ernst & Young and RMIT University, Australia's R&D performance needs boosting -- and the best way is to increase cooperation between public and private bodies.
Ethics committees must be more professional: Hall
23 July, 2003 by Pete YoungEthics committees helping to oversee bio-research need to be put on a more professional footing, according a leading member of Australia’s ethics community, Prof Wayne Hall.
Red letter day for synchrotron project
23 July, 2003 by Melissa TrudingerCalling today a "red letter day" for the Australian National Synchrotron project, Victorian Minister for Innovation, John Brumby, announced that Australian construction company Thiess was the successful tenderer to design and construct the building to house the 67 metre diameter machine, 30 plus beamlines, and associated laboratories, offices and technical facilities.
Monash boosted by Agilent equipment grant
18 July, 2003 by Melissa TrudingerMonash biomedical science students will get hands-on experience with mass spectrometry thanks to a US$150,000 equipment grant from Agilent Technologies awarded to the School of Biomedical Sciences today.
Biomedoz to close
16 July, 2003 by Jeremy TorrOnline industry and share market watcher Biomedoz has called it a day. Last week, the site posted a note informing users that it would close "in the next couple of days".
Macquarie launches 'virtual' biotech institute
16 July, 2003 by Jeremy TorrMacquarie University has linked together several of its existing departments, along with outside interests to build its own 'virtual' biotech research institute.
Forum to chew on alliance issues
14 July, 2003 by Iain ScottA special BioBusiness Forum will be held in Sydney on July 22 to go over issues raised by the recent Biotechnology Alliance signed by the premiers of NSW, Victoria and Queensland.
New “pragmatic” consulting venture
08 July, 2003 by Jeremy TorrEx-Ambri CEO Dr Joe Shaw is to set up shop in Australia with a new biotech business consulting group – the Aus-American Group Inc (AAGI) – designed to help startups navigate the Pacific Trench minefield.
Queensland govt scores top marks in bioscience
07 July, 2003 by Peter YoungVictoria trails Queensland among state governments that are energetically supporting bioscience and needs to fine-tune its Bio 21 initiative, according to one of the bioIT industry's most unusual executives, Michael Armitage.
Bio 21 initiative needs tuning: SGI executive claims
02 July, 2003 by Pete YoungVictoria trails Queensland among state governments which are energetically supporting bioscience and needs to fine-tune its Bio 21 initiative, according to one of the bioIT industry's most unusual executives, Michael Armitage.
Vita Life Sciences de-lists
02 July, 2003 by Jeremy TorrReeling under a double-whammy from an allegedly fraudulent former employee and the collapse of supplier Pan Pahramaceuticals, beleaguered nutraceutical Vita Life Sciences had delisted from the ASX.
